Post-earnings recap
Reported
Wed, Nov 9, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Cytek Biosciences reported a positive surprise on EPS, indicating profitability, but the stock fell by 5.65% in reaction. The lack of revenue details and guidance may have contributed to investor uncertainty, leading to the stock decline despite the EPS beat.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.04 | N/A | +100.00% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.